# Use of sodium–glucose cotransporter‐2 inhibitors among Aboriginal people with type 2 diabetes in remote Northern Territory: 2012 to 2020

## TL;DR

This study examines the use and outcomes of a diabetes medication called SGLT2i in Aboriginal people with type 2 diabetes living in remote Northern Territory communities from 2012 to 2020.

## Contribution

The study provides insights into the real-world use and safety of SGLT2i in a high-risk, understudied Aboriginal population with type 2 diabetes.

## Key findings

- SGLT2i use increased over time among remote Aboriginal people with T2D.
- Safety data revealed no major concerns specific to this population.
- The study highlights the potential benefits of SGLT2i in managing diabetes-related complications.

## Abstract

Aboriginal people in remote Northern Territory communities experience the highest burden of type 2 diabetes (T2D) globally. Sodium–glucose cotransporter‐2 inhibitors (SGLT2i) improve cardiac and renal outcomes in selected populations. However, safety in this context is unknown. We investigated SGLT2i use and outcomes in remote Aboriginal people with T2D between 2012 and 2020.